Rein Therapeutics Inc. (RNTX) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 5.23M | 3.96M | 5.49M | 6.87M | 5.61M | 5.8M | 6.07M | 9.04K | 7.21K | 7.29K | 1.98K | 1.99K |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 2.16M | 1.96M | 3.81M | 2.58M | 2.56M | 2.48M | 2.35M | 5.3K | 3.74K | 5.33K | 1.96K | 1.89K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 3.07M | 2M | 1.68M | 4.29M | 3.05M | 3.32M | 3.72M | 3.74K | 3.46K | 1.97K | 22 | 187 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -12 | 6 | -88 |
| Operating Income | -5.23M | -3.96M | -5.49M | -6.87M | -5.61M | -5.8M | -6.07M | -9.04K | -7.21K | -7.29K | -1.98K | -1.99K |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 6.76% | 31.71% | 9.54% | -75915.05% | -77748.72% | -79419.89% | -306052.29% | -353.77% | - | - | - | - |
| EBITDA | -5.23M | -3.87M | -5.49M | -6.87M | -5.61M | -42.52M | -5.85M | -9.04K | -7.15K | -7.24K | -1.97K | -1.98K |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 6.76% | 90.9% | 6.07% | -75937.63% | -78391.46% | -587424.18% | -296551.45% | -356.31% | - | - | - | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 1K | 0 | 0 | 0 | 4 | 59 | 52 | 12 | 12 |
| EBIT | -5.23M | -3.87M | -5.49M | -6.87M | -5.61M | -42.52M | -5.85M | -9.04K | -7.21K | -7.3K | -1.98K | -2.08K |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 700 | 0 | 0 | 0 | 600 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 700 | 0 | 0 | 0 | 600 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -608K | -28.72M | -89K | 49K | 108K | -36.73M | 224K | 97 | 92 | -49 | 156 | 205 |
| Pretax Income | -5.84M | -32.68M | -5.58M | -6.82M | -5.5M | -42.52M | -5.85M | -8.94K | -7.11K | -7.34K | -1.83K | -1.79K |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | -712K | 0 | 0 | 0 | -1.54M | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 2.18% | 0% | 0% | 0% | 3.63% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -5.84M | -31.97M | -5.58M | -6.82M | -5.5M | -40.98M | -5.85M | -8.94K | -7.11K | -7.34K | -1.83K | -1.79K |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -6.13% | 22% | 4.55% | -76191.66% | -77237.27% | -558300.33% | -319932.84% | -400.39% | - | - | - | - |
| Net Income (Continuing) | -5.84M | -31.97M | -5.58M | -6.82M | -5.5M | -40.98M | -5.85M | -8.94K | -7.11K | -7.34K | -1.83K | -1.79K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.19 | -1.22 | -0.21 | -0.28 | -0.24 | -1.89 | -0.27 | -0.45 | -0.86 | -1.54 | -0.40 | -0.39 |
| EPS Growth % | 20.83% | 35.45% | 22.22% | 37.78% | 72.09% | -22.73% | 32.5% | -15.38% | - | - | - | - |
| EPS (Basic) | -0.19 | -1.22 | -0.21 | -0.28 | -0.24 | -1.89 | -0.27 | -0.45 | -0.86 | -1.54 | -0.40 | -0.39 |
| Diluted Shares Outstanding | 30.35M | 25.44M | 26.36M | 24.19M | 22.94M | 21.69M | 21.66M | 19.91M | 8.3M | 4.77M | 4.54M | 4.54M |
| Basic Shares Outstanding | 30.35M | 25.44M | 26.36M | 24.19M | 22.94M | 21.69M | 21.66M | 19.91M | 8.3M | 4.77M | 4.54M | 4.54M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |